HIV prevention pill study aims to Fine-Tune protection for women
NCT ID NCT05140954
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective a daily HIV prevention pill (TAF-FTC) is in 54 Kenyan cisgender women. Participants took different numbers of doses each week to mimic real-world use. The goal was to measure drug levels in the blood and tissues, helping doctors better understand how well the pill works in women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kenya Medical Research Institute - Partners in Health Research and Development
Thika, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?